Pregnancy Medication Market (By Type: Drug Class, Nutritional Supplements, Others; By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy; By Pregnancy Stage: 3rd-trimester, 1st trimester, 2nd trimester) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
The global pregnancy medication market size was valued at USD 39.68 billion in 2023 and is estimated to reach around USD 135.43 billion by 2033 growing at a CAGR of 13.06% from 2024 to 2033.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The pregnancy medication market refers to the pharmaceutical sector focused on developing, manufacturing, and marketing medications specifically intended for use during pregnancy. These medications are designed to address various health conditions and concerns that may arise before, during, or after pregnancy, with the primary goal of ensuring the health and well-being of both the mother and the developing fetus. The pregnancy medication market includes medications used to manage various pregnancy-related conditions and complications, such as morning sickness, gestational diabetes, hypertension, preterm labor, and preeclampsia. These medications may include antiemetics, antidiabetic agents, antihypertensives, tocolytics, and corticosteroids, among others.
Report Coverage | Details |
Growth Rate from 2024 to 2033 | CAGR of 13.06% |
Global Market Size in 2023 | USD 39.68 Billion |
Global Market Size by 2033 | USD 135.43 Billion |
Largest Market | North America |
Base Year | 2023 |
Forecast Period | 2024 to 2033 |
Segments Covered | By Type, By Distribution Channel, and By Pregnancy Stage |
Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Driver: Rising emphasis on treating nutritional deficiencies during pregnancy
The rising focus on treating nutritional deficiencies during the pregnancy phase to avoid major drawbacks after delivery is observed to act as a major driver for the pregnancy medication market. Increased awareness and education among pregnant women about the importance of nutrition and prenatal care contribute to the demand for pregnancy medications. Pregnant women are often proactive in seeking out information and resources to support their health and the health of their baby during pregnancy. Healthcare providers play a crucial role in educating pregnant women about the benefits of specific medications and supplements for addressing nutritional deficiencies and promoting a healthy pregnancy.
Pregnancy places increased nutritional demands on the mother's body to support the growth and development of the fetus. Inadequate nutrient intake during pregnancy can lead to maternal health issues such as anemia, gestational diabetes, preeclampsia, and postpartum complications. Medications and supplements designed to address specific nutritional deficiencies help support maternal nutrition and overall well-being during pregnancy, reducing the risk of maternal complications and improving pregnancy outcomes.
Restraint: High cost
The high cost associated with pregnancy medication is anticipated to hamper the pregnancy medication market's growth. Pregnancy medications are generally expensive and pregnant women need to go through ultrasound many times during the period of pregnancy. A significant amount is needed to purchase pregnancy drugs discourages women staying in the backward or underdeveloped areas. In addition, adverse side effects are associated with many pregnancy drugs which may lead to complications during the period of pregnancy, which may restrict the expansion of the global market.
Opportunity: Public health initiatives
Governments may allocate funding and grants to support research and development efforts in the field of pregnancy medication. Research funding from government agencies, such as the National Institutes of Health (NIH) or the European Commission, can accelerate the discovery and development of new medications for pregnancy-related conditions, such as gestational diabetes, preeclampsia, and preterm labor. Government-sponsored research initiatives can also facilitate collaborations between academia, industry, and healthcare providers to address unmet medical needs in maternal-fetal medicine.
Governments often collaborate with private sector stakeholders, including pharmaceutical companies, healthcare providers, and nonprofit organizations, to improve maternal and child health outcomes. Public-private partnerships may involve joint initiatives to develop and distribute pregnancy medications, provide educational resources and support services for pregnant women, and implement community-based interventions to address maternal health disparities. By leveraging the resources and expertise of both public and private sectors, governments can enhance the effectiveness and impact of interventions in the pregnancy medication market.
In 2023, the drug class segment dominated the pregnancy medication market. Under the segment, the antacids sub-segment accounted for the dominating share in the market. During pregnancy, the hormonal changes or the increasing baby pressing on the stomach may lead to indigestion, heartburn, or acid reflux in pregnant women. Antacids are recommended as first-line treatment for heartburn and acid reflux during pregnancy. Therefore, the use of Antacids coupled with the increasing availability of medicine over-the-counter platforms is expected to accelerate the segment’s growth.
The antianemia sub-segment is observed to witness a considerable growth in the global pregnancy medications market over the forecast period. Antianemia medications prescribed during pregnancy are generally considered safe and effective when used as directed under the supervision of healthcare professionals. Iron supplements are available in various formulations, including oral tablets, capsules, and liquid preparations, making them convenient and easy to administer. Healthcare providers monitor maternal iron levels throughout pregnancy and adjust supplementation as needed to optimize iron stores and prevent anemia-related complications.
National and international health organizations, such as the World Health Organization (WHO) and the American College of Obstetricians and Gynecologists (ACOG), recommend routine iron supplementation for pregnant women to prevent and treat iron deficiency anemia. These guidelines are widely adopted by healthcare providers and form the basis for prenatal care protocols and antenatal screening programs. As a result, antianemia medications are routinely prescribed as part of standard prenatal care for pregnant women.
The hospital pharmacy segment held the largest share of 2023 the pregnancy medication market in 2023. Hospitals often serve as primary points of care for pregnant women, particularly those with high-risk pregnancies or medical complications. Hospital pharmacies within these facilities are well-equipped to dispense a wide range of pregnancy medications prescribed by obstetricians, maternal-fetal medicine specialists, and other healthcare providers. This direct access to specialized care drives a significant portion of the demand for pregnancy medications within hospital settings.
Some pregnant women require hospitalization for the management of pregnancy-related complications, such as gestational diabetes, hypertension, or preterm labor. During hospital stays, patients may receive medications to control blood sugar levels, lower blood pressure, or prevent premature delivery. Hospital pharmacies are responsible for dispensing these medications and coordinating with healthcare teams to ensure appropriate medication management and monitoring.
The online pharmacy segment is observed to witness the fastest rate of expansion during the forecast period. The expansion of e-commerce sector, especially in urban areas promotes the segment’s expansion in the market. Online pharmacies often offer a broader selection of pregnancy medications and related products compared to traditional pharmacies. Expectant mothers can choose from a variety of brands, formulations, and dosage forms to meet their specific needs and preferences. Additionally, online platforms may stock specialty or niche products that may not be readily available in local pharmacies.
Online pharmacies typically provide comprehensive information and educational resources about pregnancy medications, including dosage instructions, potential side effects, and safety precautions. Expectant mothers can access this information at their convenience, empowering them to make informed decisions about their healthcare and medication management during pregnancy.
The 3rd-trimester segment held the largest share of the pregnancy medication market in 2023. period. The 3rd-trimester pregnancy involves the development and maturing of the brain, kidney, and lungs of the fetus in the mother’s womb, which increases the nutritional requirements for the pregnant woman. Gynecologists prescribe a patient to increase their intake of protein and iron supplements to reduce the chances of anemia and boost the overall healthy development of the unborn child. Thus, the 3rd-trimester of pregnancy increases the demand for pregnancy medication such as antianemia, antacids, antiallergic, and other nutritional supplements. Thereby, the segment becomes the most prominent one in the market.
North America dominated the pregnancy medication market in 2023. The region is observed to witness a significant growth rate during the forecast period. The growth of the region is attributed to the presence of prominent pharmaceutical companies, rising healthcare spending and rising research and development activities, Moreover, the ongoing awareness campaigns regarding pregnancy care, and increasing incidences of pregnancy-related complications which results in increasing demand for pregnancy medication in the region.
The United States and Canada are the major contributors to the pregnancy medications market owing to the presence of sophisticated healthcare infrastructure, increasing product approvals by various regulatory bodies, rising disposable income, increasing women's inclination toward pregnancy medication for the treatment of chronic diseases, and rising cases of pregnancy.
Asia Pacific is observed to witness the fastest rate of growth in the pregnancy medication market during the forecast period. The pharmaceutical industry in Asia Pacific is experiencing rapid growth and expansion, with many multinational pharmaceutical companies establishing a strong presence in the region. Local pharmaceutical manufacturers are also emerging as key players, producing a wide range of pregnancy medications to meet domestic and regional demand. Governments in the Asia Pacific are implementing various initiatives and policies to improve maternal and child health outcomes. This includes programs to increase access to prenatal care, maternal education, and essential medications for pregnant women. Government support and funding for maternal healthcare contribute to the expansion of the pregnancy medication market in the region.
Segments Covered in the Report
By Type
By Distribution Channel
By Pregnancy Stage
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Pregnancy Medication Market
5.1. COVID-19 Landscape: Pregnancy Medication Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Pregnancy Medication Market, By Type
8.1. Pregnancy Medication Market Revenue and Volume, by Type, 2024-2033
8.1.1 Drug Class
8.1.1.1. Market Revenue and Volume Forecast (2021-2033)
8.1.2. Nutritional Supplements
8.1.2.1. Market Revenue and Volume Forecast (2021-2033)
8.1.3. Others
8.1.3.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 9. Global Pregnancy Medication Market, By Distribution Channel
9.1. Pregnancy Medication Market Revenue and Volume, by Distribution Channel, 2024-2033
9.1.1. Hospital Pharmacy
9.1.1.1. Market Revenue and Volume Forecast (2021-2033)
9.1.2. Retail Pharmacy
9.1.2.1. Market Revenue and Volume Forecast (2021-2033)
9.1.3. Online Pharmacy
9.1.3.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 10. Global Pregnancy Medication Market, By Pregnancy Stage
10.1. Pregnancy Medication Market Revenue and Volume, by Pregnancy Stage, 2024-2033
10.1.1. 3rd-trimester
10.1.1.1. Market Revenue and Volume Forecast (2021-2033)
10.1.2. 1st trimester
10.1.2.1. Market Revenue and Volume Forecast (2021-2033)
10.1.3. 2nd trimester
10.1.3.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 11. Global Pregnancy Medication Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.1.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.1.3. Market Revenue and Volume Forecast, by Pregnancy Stage (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.1.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.1.4.3. Market Revenue and Volume Forecast, by Pregnancy Stage (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.1.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.1.5.3. Market Revenue and Volume Forecast, by Pregnancy Stage (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.2.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.2.3. Market Revenue and Volume Forecast, by Pregnancy Stage (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.2.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.2.4.3. Market Revenue and Volume Forecast, by Pregnancy Stage (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.2.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.2.5.3. Market Revenue and Volume Forecast, by Pregnancy Stage (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.2.6.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.2.6.3. Market Revenue and Volume Forecast, by Pregnancy Stage (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.2.7.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.2.7.3. Market Revenue and Volume Forecast, by Pregnancy Stage (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.3.3. Market Revenue and Volume Forecast, by Pregnancy Stage (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.3.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.3.4.3. Market Revenue and Volume Forecast, by Pregnancy Stage (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.3.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.3.5.3. Market Revenue and Volume Forecast, by Pregnancy Stage (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.3.6.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.3.6.3. Market Revenue and Volume Forecast, by Pregnancy Stage (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.3.7.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.3.7.3. Market Revenue and Volume Forecast, by Pregnancy Stage (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.4.3. Market Revenue and Volume Forecast, by Pregnancy Stage (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.4.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.4.4.3. Market Revenue and Volume Forecast, by Pregnancy Stage (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.4.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.4.5.3. Market Revenue and Volume Forecast, by Pregnancy Stage (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.4.6.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.4.6.3. Market Revenue and Volume Forecast, by Pregnancy Stage (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.4.7.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.4.7.3. Market Revenue and Volume Forecast, by Pregnancy Stage (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.5.3. Market Revenue and Volume Forecast, by Pregnancy Stage (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.5.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.5.4.3. Market Revenue and Volume Forecast, by Pregnancy Stage (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)
11.5.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)
11.5.5.3. Market Revenue and Volume Forecast, by Pregnancy Stage (2021-2033)
Chapter 12. Company Profiles
12.1. Roche Holding AG
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Pfizer
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Glenmark Pharmaceuticals Ltd
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Alkem Laboratories Limited
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Lupin Limited
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Amgen Inc
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. AbbVie
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Piramal Enterprises Limited
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Sanofi
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Janssen
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client